Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics, Inc. completed a private offering of $275.0 million of 0.75% Convertible Senior Notes due 2032, and an additional $41.25 million from the purchasers’ option, for total notes of $316.25 million in senior unsecured debt.
The notes carry 0.75% annual interest, payable semiannually, and mature on July 1, 2032, with conversion initially at 70.6140 shares per $1,000 (about $14.16 per share), a 35% premium to the $10.49 share price on June 16, 2026. NeoGenomics entered into capped call transactions with a $20.98 cap and paid about $28.7 million for them to help limit dilution on conversion.
The company relied on private offering exemptions and may issue up to 30,147,733 shares upon conversion, based on the initial maximum conversion rate. Concurrently, it repurchased approximately $276.0 million principal of 0.25% convertible notes due 2028 for about $263.19 million and arranged up to $25.0 million of share repurchases at $10.49 per share.
NeoGenomics director Lynn A. Tetrault reported an open-market sale of 5,307 shares of Common Stock at $11.10 per share on June 15, 2026. After this transaction, she directly holds 86,115 Common shares.
She also indirectly holds 7,000 Common shares through a Lynn Tetrault Rollover IRA. In addition, she has 15,970 Restricted Stock Units tied to Common Stock and multiple stock option grants covering various numbers of underlying shares with exercise prices ranging from $8.10 to $41.76 and expirations between 2026 and 2036.
NeoGenomics, Inc. is privately offering $275 million of 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an additional $41.25 million option for initial purchasers. The notes are convertible into cash, common stock, or a mix, at the company’s election.
The initial conversion rate is 70.6140 shares per $1,000, implying a conversion price of about $14.16 per share, a 35% premium to the $10.49 last sale price. NeoGenomics expects net proceeds of about $266.15 million, or $306.16 million if the option is fully exercised.
The company plans to spend about $25 million on capped call transactions with a $20.98 cap price, repurchase $276 million principal of 0.25% convertible notes due 2028 for about $263.19 million, and may repurchase up to $25 million of common stock, using any remaining proceeds for general corporate purposes.
NeoGenomics, Inc. plans a private offering of $275 million aggregate principal amount of convertible senior notes due 2032, limited to investors reasonably believed to be qualified institutional buyers. An option may allow initial purchasers to buy up to an additional $41.25 million of notes.
The notes will be senior unsecured obligations, maturing on July 1, 2032, with semi-annual interest and investor conversion rights. NeoGenomics may redeem the notes for cash after July 6, 2029 if its share price meets a 130% conversion-price threshold. The company plans capped call transactions and expects to use proceeds to help fund these, repurchase a portion of its 0.25% convertible notes due 2028, repurchase up to $25 million of common stock from certain note purchasers, and for general corporate purposes.
NeoGenomics (NEO) affiliate sale reported. Lynn Tetrault executed a 10b5-1 sale of 5,307 shares of Common Stock on 06/09/2026. The filing lists proceeds of $59,905.42. The record also shows 5,307 Restricted Stock Units dated 06/01/2026.
NEOGENOMICS INC director Lynn A. Tetrault sold 5,307 shares of common stock at $11.29 per share in an open-market transaction on June 9, 2026. After this sale, she directly held 91,422 common shares and indirectly held 7,000 shares through a Lynn Tetrault Rollover IRA.
She also reported equity awards that can convert into common stock, including 15,970 restricted stock units and multiple stock option grants covering tens of thousands of shares at exercise prices ranging from $8.10 to $41.76 per share with expirations between 2026 and 2036.
NeoGenomics Inc. director John P. Kenny reported equity compensation and an option exercise involving company stock. He exercised restricted stock units into 5,893 shares of common stock at $0.00 per share and now holds 5,893 common shares directly.
He also received a grant of 15,970 restricted stock units and 11,069 stock options exercisable at $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. A separate stock option covering 4,171 shares at an exercise price of $11.76 remains outstanding and is scheduled to expire on January 1, 2036.
NeoGenomics, Inc. director Felicia Williams reported multiple equity compensation events. She exercised previously granted restricted stock units, receiving 23,077 shares of common stock at a price of $0.00 per share, and now directly owns 30,237 common shares following the transactions.
She was also granted 15,970 restricted stock units and 11,069 stock options with an exercise price of $10.52 per share, both relating to NeoGenomics common stock. In addition, she continues to hold options covering 16,107 shares at an exercise price of $7.28 per share expiring June 1, 2035, and 5,430 shares at $13.59 per share expiring June 1, 2034.
NeoGenomics director Lynn A. Tetrault reported equity award activity and updated holdings. On 2026-06-01, she acquired 23,077 shares of Common Stock through the exercise of previously reported restricted stock units at $0.00 per share, bringing her direct Common Stock holdings to 96,729 shares.
She also received new equity compensation in the form of 15,970 Restricted Stock Units and 11,069 Stock Options with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on 2027-06-01. In addition, she holds 7,000 shares of Common Stock indirectly through the Lynn Tetrault Rollover IRA and maintains several previously granted option positions with exercise prices ranging from $7.28 to $41.76 and expirations through 2035.